Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Looking to the future: How can emerging therapeutic options influence the management landscape?
Date
14 Sep 2020Session
Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizonPresenters
Benjamin BesseAuthors
L.V. Sequist1, B. Besse2Author affiliations
- 1 Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
- 2 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
Resources
Resources from the same session
Uncommon EGFR mutations in NSCLC
Presenter: Zofia Piotrowska
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast
Live Q&A - 18 September 2020 - 15:30-16:00
Presenter: Pilar Garrido
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast
An overview of NSCLC
Presenter: Marina Garassino
Session: Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Resources:
Webcast